Contextual reprogramming of CAR-T cells for treatment of HER2(+) cancers

BACKGROUND: Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells combined with checkpoint inhibition may prevent T cell exhaustion and improve clinical outcomes. However, the approach is limited by cumulative costs and toxicities. METHODS: To overcome this drawback, we created a C...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhifen, Li, Lingyu, Turkoz, Ahu, Chen, Pohan, Harari-Steinfeld, Rona, Bobbin, Maggie, Stefanson, Ofir, Choi, Hana, Pietrobon, Violena, Alphson, Bennett, Goswami, Angshumala, Balan, Vitaly, Kearney, Alper, Patel, Dharmesh, Yang, Jin, Inel, Damla, Vinod, Veena, Cesano, Alessandra, Wang, Bing, Roh, Kyung-Ho, Qi, Lei S., Marincola, Francesco M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573881/
https://www.ncbi.nlm.nih.gov/pubmed/34743703
http://dx.doi.org/10.1186/s12967-021-03132-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573881/
https://www.ncbi.nlm.nih.gov/pubmed/34743703
http://dx.doi.org/10.1186/s12967-021-03132-6

Ejemplares similares